Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423698 | 0.98 | NPSR1 (0.78) | NPSR1ALDH1A1NPC1KDM4ECA12 | |
| SCHEMBL13165679 | 0.90 | NPSR1 (1.00) | NPSR1ALDH1A1KDM4EMAPK1HIF1A | |
| SCHEMBL13993828 | 0.82 | NPSR1 (0.83) | NPSR1ALDH1A1KDM4ECA12CA2 | |
| SCHEMBL24737682 | 0.80 | NPSR1 (0.72) | NPSR1KDM4ECA12CA1CA2 | |
| SCHEMBL14385466 | 0.80 | NPSR1 (0.72) | NPSR1ALDH1A1KDM4EHTTTDP1 | |
| SCHEMBL16425172 | 0.79 | NPSR1 (0.69) | NPSR1ALDH1A1NPC1KDM4EHTT | |
| SCHEMBL10278655 | 0.79 | NPSR1 (0.52) | NPSR1ALDH1A1NPC1KDM4ECA12 | |
| SCHEMBL11421204 | 0.78 | ALDH1A1 (0.50) | NPSR1ALDH1A1NPC1CA12CA1 | |
| SCHEMBL2755861 | 0.78 | NPSR1 (0.50) | NPSR1ALDH1A1NPC1KDM4ECA12 | |
| SCHEMBL6242026 | 0.77 | NPSR1 (0.50) | NPSR1ALDH1A1NPC1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| EP-2440519-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-04-18 | — | — | EP | claimed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | claimed |
| WO-2010144371-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INIHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | claimed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | claimed |
| WO-2010133836-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | WO | claimed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-07-21 | — | — | US | disclosed |
| EP-3990459-A1 | IMIDAZOPYRIDINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3990451-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-05-04 | — | — | EP | disclosed |
| EP-1583757-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| WO-2004058743-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | NPSR1 4717/4885ALDH1A1 1807/4885NPC1 3094/4885 |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | NPSR1 4590/4885ALDH1A1 1119/4885NPC1 3724/4885 |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | NPSR1 4211/4885ALDH1A1 339/4885NPC1 506/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | NPSR1 4211/4885ALDH1A1 339/4885NPC1 506/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | NPSR1 2753/4885ALDH1A1 367/4885NPC1 2668/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | NPSR1 3597/4885ALDH1A1 1059/4885NPC1 3977/4885 |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | NPSR1 3298/4885ALDH1A1 1152/4885NPC1 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.